Citations

Clear

1825 citation(s) found for "Yu, Emily".

Interferon Chemokine Score and Other Cytokine Measures Track With Changes in Disease Activity in Patients With Juvenile and Adult Dermatomyositis
Crowson, Cynthia S. , Hein, Molly S., Pendegraft, Richard S., Strausbauch, Michael, Niewold, Timothy B. , Ernste, Floranne C. , Dvergsten, Jeffrey , Amin, Shreyasee , Muskardin, Theresa Wampler , Baechler, Emily C., Reed, Ann M. , Strausbauch, Michael A, Reed, Ann M , Peterson, Erik J

Mayo Clinic

ACR Open Rheumatology | April 11, 2019 | Volume: 1 | Issue: 2 | Pages: 83-89

10.1002/acr2.1011 | PMID 31777784 Get It

ObjectiveOur aim was to identify cytokines and chemokines in patients with adult dermatomyositis (DM) and juvenile dermatomyositis (JDM) that predict changes in disease activity.MethodsMultiplexed immunoassays (Meso Scale Discovery) enabled simultaneous measurement of interferon (IFN)‐regulated chemokines and other pro‐ and anti‐inflammatory cytokines specific to differentiation of specific T‐cell and innate pathways. Cytokine scores were computed for IFNCK (IP‐10, MCP‐1), Th1 (IFNɣ, TNFα, and IL2), Th2 (IL4, IL10, IL12, and IL 13), Th17 (IL6, IL17, IL1β), macrophage (MIP‐1α, MIP‐1β, IL8), and regulatory (IL10, TNFα) factors. Spearman correlation and mixed models were used to examine whether cytokines at a previous visit predict change in disease activity at the next visit.ResultsThe study included 36 patients (16 DM and 20 JDM) with at least two visits (87 patient intervals between two visits). Mean age (SD) at inclusion was 56.9 (18.4) years for DM and 10.8 (6.6) years in JDM, 67% of patients were female, 89% Caucasian. The mean (SD) physician global, muscle and extra‐muscular disease activity Visual Analog Scale scores at inclusion were 41 (26), 36 (30), and 34 (21) mm, respectively. The change in IFN score from one visit to the next was associated with the change in physician global (P = 0.010) and extramuscular (P < 0.001) disease activity scores. Preliminary results revealed significant correlations of previous IFNCK score and IL‐6 with subsequent disease activity measures, but after adjustment for multiple visits per patient, these associations did not reach statistical significance.ConclusionThere is a potential relationship between IFNCK and other cytokine scores seen in adult and juvenile DM with future disease states.
Pharmacological clearance of senescent cells improves survival and recovery in aged mice following acute myocardial infarction
Walaszczyk, Anna , Dookun, Emily , Redgrave, Rachael E. , Tual‐Chalot, Simon , Victorelli, Stella , Spyridopoulos, Ioakim , Owens, W. Andrew , Arthur, Helen M. , Passos, João F. , Richardson, Gavin D. , Spyridopoulos, Ioakim , Arthur, Helen M , Passos, João F , Richardson, Gavin D

Mayo Clinic

Aging Cell | March 28, 2019 | Volume: 18 | Issue: 3 | Pages: No page available

10.1111/acel.12945 | PMID 30920115 Get It

Abstract Cardiovascular disease is the leading cause of death in individuals over 60 years old. Aging is associated with an increased prevalence of coronary artery disease and a poorer prognosis following acute myocardial infarction (MI). With age, senescent cells accumulate in tissues, including the heart, and contribute to age‐related pathologies. However, the role of senescence in recovery following MI has not been investigated. In this study, we demonstrate that treatment of aged mice with the senolytic drug, navitoclax, eliminates senescent cardiomyocytes and attenuates profibrotic protein expression in aged mice. Importantly, clearance of senescent cells improved myocardial remodelling and diastolic function as well as overall survival following MI. These data provide proof‐of‐concept evidence that senescent cells are major contributors to impaired function and increased mortality following MI and that senolytics are a potential new therapeutic avenue for MI.
Clinicopathological, immunophenotypic and genetic studies of mediastinal paragangliomas†
Hsu, Ying-Han R, Torres‐Mora, Jorge , Kipp, Benjamin R. , Sukov, William R. , Jenkins, Sarah M. , Voss, Jesse S. , Cassivi, Stephen D. , Roden, Anja C. , Barr Fritcher, Emily G, Hsu, Ying-Han R. , Fritcher, Emily G. Barr , Schaff, Hartzell V.

Mayo Clinic

European Journal of Cardio-Thoracic Surgery | March 21, 2019 | Volume: 56 | Issue: 5 | Pages: 867-875

10.1093/ejcts/ezz115 | PMID 31329844 Get It

Abstract OBJECTIVES Paragangliomas have unique features in the mediastinum, in part due to their location. Because of their paucity, they have not been thoroughly investigated. We studied the clinical, pathological, immunohistochemical and molecular features of mediastinal paragangliomas. METHODS Immunohistochemistry, next-generation sequencing mutation panel and the Oncoscan assay were performed. RESULTS Twenty-four patients with mediastinal paraganglioma (7 men, 29.2%) had a median age of 45.5 years (19.8–72.2). Twenty-one (87.5%) paragangliomas were completely resected. Six (of 24, 25.0%) tumours were considered metastatic. Mitotic activity occurred in 11 (of 24, 45.8%) paragangliomas. Programmed death-ligand 1 (PD-L1) (n = 23) was expressed in 6 (26%) patients in 10% (n = 2) and 1% (n = 4) of tumour cells, respectively. SDHB expression was lost in 19 (of 22, 86.4%) cases. ATRX expression was lost in 11 (of 23, 47.8%) cases. Next-generation sequencing revealed a single pathogenic mutation in 10 (of 19) specimens including SDHB (n = 4), SDHD (n = 6), SDHC (n = 1), ATRX (n = 1), and ≥2 mutations in 2 cases [SDHC and TERT (n = 1); SDHB, ATRX and TP53 (n = 1)]. Germline mutation analysis revealed the same succinate dehydrogenase mutation (or lack thereof) as identified in the paraganglioma in 11 (of 12) cases. During a median follow-up (n = 21) of 4.8 years (0.8–14.9), 3 patients developed metastases; 4 patients died, at least 1 of disease. CONCLUSIONS Mediastinal paragangliomas can be associated with morbidity and mortality. Many mediastinal paragangliomas have been reported to be associated with syndromes such as multiple endocrine neoplasia, von Hippel-Lindau or succinate dehydrogenase syndrome with mutation profiles dominated by alterations in genes associated with these syndromes.
Coordinated follow-up Breast Cancer Survivorship Care Program study.
Ruddy, Kathryn J. , Baker, Emily, Goldstein, Matthew , Mullaney, Erin E., Shulman, Lawrence N. , Partridge, Ann H.

Mayo Clinic

Journal of Clinical Oncology | March 7, 2019 | Volume: 33 | Issue: 15_suppl | Pages: e17727-e17727

10.1200/jco.2015.33.15_suppl.e17727 Get It

Influence of molecular alterations on site-specific (ss) time to recurrence (TTR) following adjuvant therapy in resected colon cancer (CC) (Alliance Trial N0147).
Wilcox, Ryan Eldredge, Foster, Nathan R. , Meyers, Jeffrey P., Goldberg, Richard M. , Nair, Suresh , Shields, Anthony F. , Chan, Emily , Kahlenberg, Morton S., Shi, Qian , Sinicrope, Frank A. , Sargent, Daniel J. , Gill, Sharlene , Alberts, Steven R.

Mayo Clinic

Journal of Clinical Oncology | March 7, 2019 | Volume: 33 | Issue: 15_suppl | Pages: 3590-3590

10.1200/jco.2015.33.15_suppl.3590 Get It

Relationship between metformin use and recurrence and survival in patients (pts) with resected stage III colon cancer (CC) receiving adjuvant chemotherapy: Results from NCCTG N0147 (Alliance).
Foster, Nathan R. , Grothey, Axel, Chan, Emily , Shields, Anthony F. , Goldberg, Richard M. , Kahlenberg, Morton S., Singh, Preet Paul , Shi, Qian , Nair, Suresh, Gill, Sharlene , Sinicrope, Frank A. , Sargent, Daniel J. , Alberts, Steven R.

Mayo Clinic

Journal of Clinical Oncology | March 7, 2019 | Volume: 33 | Issue: 15_suppl | Pages: 3531-3531

10.1200/jco.2015.33.15_suppl.3531 Get It

Alcohol consumption and prognosis in patients with stage III colon cancer: A correlative analysis of phase III trial NCCTG N0147 (Alliance).
Phipps, Amanda I. , Nelson, Garth D. , Chan, Emily , Goldberg, Richard M. , Kahlenberg, Morton S., Nair, Suresh , Shields, Anthony F. , Shi, Qian , Limburg, Paul J. , Sargent, Daniel J. , Sinicrope, Frank A. , Gill, Sharlene , Newcomb, Polly A. , Alberts, Steven R.

Mayo Clinic

Journal of Clinical Oncology | March 7, 2019 | Volume: 33 | Issue: 15_suppl | Pages: 1508-1508

10.1200/jco.2015.33.15_suppl.1508 Get It

Adjuvant aromatase inhibitor adherence based on the Morisky Medication Adherence Scale and identification of predictors to adherence.
Rosenblatt, Paula , Goloubeva, Olga, Bellavance, Emily, Chumsri, Saranya , Nichols, E.M. , Feigenberg, Steven J. , Tait, Nancy, Tkaczuk, Katherine H. R., Kesmodel, Susan B , Bao, Ting , Heiss, Brian L.

Mayo Clinic

Journal of Clinical Oncology | March 7, 2019 | Volume: 33 | Issue: 15_suppl | Pages: 555-555

10.1200/jco.2015.33.15_suppl.555 Get It